![Brian Burkavage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Brian Burkavage
Director of Finance/CFO at
DAMORA THERAPEUTICS, INC.
Net worth: 35 $ as of 30/05/2026
Profile
Brian Burkavage is Chief Financial & Accounting Officer at Damora Therapeutics, Inc. starting in 2026.
Former positions include Chief Accounting Officer at IO Biotech, Inc. from 2022 to 2025, Controller at Passage Bio, Inc. from 2020 to 2021, and Director-Financial Planning & Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.
Education includes undergraduate and graduate degrees from the University of Notre Dame.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IO BIOTECH, INC. 0.02% | 01/04/2025 | 11,500 ( 0.02% ) | 35 $ | 30/05/2026 |
Brian Burkavage active positions
| Companies | Position | Start |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Director of Finance/CFO | 30/04/2026 |
Former positions of Brian Burkavage
| Companies | Position | End |
|---|---|---|
| IO BIOTECH, INC. | Comptroller/Controller/Auditor | 11/12/2025 |
| PASSAGE BIO, INC. | Comptroller/Controller/Auditor | 31/12/2020 |
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/2019 |
Training of Brian Burkavage
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
20
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
- Stock Market
- Insiders
- Brian Burkavage
